Piper Sandler analyst Matt O’Brien raised the firm’s price target on Miromatrix Medical to $9 from $8 and keeps an Overweight rating on the shares. While the company underperformed expectations in Q3, the main focus will remain on the preclinical progress of the company’s bioengineered organs for the foreseeable future, and to that end, Miromatrix announced the recent submission of its IND for the miroliverELAP, its external liver assist product, the analyst tells investors in a research note. The current capitalization does not reflect the massive end markets that Miromatrix will play in, O’Brien adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MIRO:
- Miromatrix CEO Jeff Ross Delivering Keynote Address at ARMI | BioFabUSA 2022 Fall Summit: Meeting in the Millyard
- Miromatrix Medical management to meet with Piper Sandler
- Miromatrix CEO Jeff Ross to Present at the 2022 Cell & Gene Meeting on the Mesa
- William Blair biotech analysts to hold analyst/industry webinar
- Miromatrix CEO Jeff Ross to Present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event